Navigation Links
Cadence Pharmaceuticals to Host Conference Call and Webcast to Discuss Fourth Quarter and Full Year 2010 Financial Results on March 4, 2011
Date:2/25/2011

SAN DIEGO, Feb. 25, 2011 /PRNewswire/ -- Cadence Pharmaceuticals, Inc. (Nasdaq: CADX), a biopharmaceutical company focused on in-licensing, developing and commercializing proprietary product candidates principally for use in the hospital setting, today announced that it will release its fourth quarter and full year ended December 31, 2010 financial results on Friday, March 4, 2011.

Cadence management will host a conference call and live webcast to discuss the financial results on Friday, March 4, 2011 at 5:30 am Pacific Time (8:30 am Eastern Time). Interested investors may participate in the conference call by dialing (877) 303-9145 (domestic) or (760) 536-5203 (international).  To access the webcast, please visit the company's website at www.cadencepharm.com and go to the Investor Relations page.  A replay of the webcast will be available approximately two hours after the call and remain available on the company's website until the next quarterly financial results call.

About Cadence Pharmaceuticals, Inc.Cadence Pharmaceuticals is a biopharmaceutical company focused on in-licensing, developing and commercializing proprietary product candidates principally for use in the hospital setting. For more information about Cadence's pipeline, visit www.cadencepharm.com.Contacts:

William R. LaRueSVP & Chief Financial OfficerCadence Pharmaceuticals, Inc.858-436-1400
'/>"/>

SOURCE Cadence Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1

Related biology technology :

1. Cadence Pharmaceuticals Announces U.S. Launch and Availability of OFIRMEV™ (acetaminophen) Injection
2. Cadence Pharmaceuticals Announces FDA Approval of OFIRMEV™ (acetaminophen) injection for the Management of Pain and Fever
3. Cadence Pharmaceuticals to Host Conference Call and Webcast to Discuss Third Quarter 2009 Financial Results on November 5, 2009
4. Cadence Pharmaceuticals to Present at Two Investment Conferences During the Month of September 2009
5. Cadence Pharmaceuticals Reports Second Quarter 2009 Financial Results
6. Cadence Pharmaceuticals Reports First Quarter 2009 Financial Results
7. Cadence Pharmaceuticals CEO Ted Schroeder to Present at Two Investment Conferences During the Month of May 2009
8. Cadence Pharmaceuticals Announces Presentations at Upcoming Scientific Conferences
9. Cadence Pharmaceuticals CEO Theodore Schroeder to Present at BioCentury Publications Inc. Future Leaders in the Biotech Industry Conference in New York on April 2, 2009
10. Cadence Pharmaceuticals to Host Conference Call and Webcast to Discuss Fourth Quarter and Full Year 2008 Financial Results and Corporate Update on March 12, 2009
11. Cadence Pharmaceuticals CEO Theodore Schroeder to Present at the Roth Capital Partners 21st Annual OC Growth Stock Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/2/2014)... EUGENE, Ore. -- Scientists, including University of Oregon ... to create scaffolds of self-assembling, synthetic proteins called ... processes. , The accomplishment -- detailed this week ... by the Proceedings of the National Academy ... an alternative design of the two-dimensional peptoid nanosheets ...
(Date:9/2/2014)... (PRWEB) September 02, 2014 Myriant ... the signage of a distribution agreement with Azelis ... now distributing Myriant’s bio-succinic acid in the Nordics, ... Ireland, targeting customers in the industrial and base ... powerhouse, Azelis offers a far-reaching chemical portfolio with ...
(Date:9/2/2014)... ROCKVILLE, Md. , Sept. 2, 2014 /PRNewswire/ ... of novel anti-infective biologic and drug candidates targeting ... announced today positive results from its final preclinical ... Drug Administration (FDA) guidance, this bridging study was ... product candidate designed to prevent the devastating effects ...
(Date:9/2/2014)... The inventors of tinAway, a novel treatment ... seeking support for development costs through a crowdfunding campaign. ... ), was launched on September 1, 2014. , tinAway ... is based on ten years of neuroscience research. ... software engineers, Dr. Ian Dixon and Mr. Tony Burgess, ...
Breaking Biology Technology:UO-Berkeley Lab unveil new nano-sized synthetic scaffolding technique 2Myriant and Azelis Sign European Distribution Agreement for Bio-Succinic Acid 2Synthetic Biologics to Initiate Clinical Trials of SYN-004 in 4Q 2014 to Prevent Potentially Deadly C. difficile Infections 2Synthetic Biologics to Initiate Clinical Trials of SYN-004 in 4Q 2014 to Prevent Potentially Deadly C. difficile Infections 3Synthetic Biologics to Initiate Clinical Trials of SYN-004 in 4Q 2014 to Prevent Potentially Deadly C. difficile Infections 4Synthetic Biologics to Initiate Clinical Trials of SYN-004 in 4Q 2014 to Prevent Potentially Deadly C. difficile Infections 5tinAway Pty. Ltd. launch a crowdfunding campaign to fund a clinical trial of tinAway, a new potential cure for chronic tinnitus 2tinAway Pty. Ltd. launch a crowdfunding campaign to fund a clinical trial of tinAway, a new potential cure for chronic tinnitus 3tinAway Pty. Ltd. launch a crowdfunding campaign to fund a clinical trial of tinAway, a new potential cure for chronic tinnitus 4tinAway Pty. Ltd. launch a crowdfunding campaign to fund a clinical trial of tinAway, a new potential cure for chronic tinnitus 5
... The Muscular Dystrophy Association announced today that it ... biotechnology company, to develop and test a "dissociative glucocorticoid" ... (DMD) . (Logo: http://photos.prnewswire.com/prnh/20120424/DC93207LOGO ) ... Institutes of Health Therapeutics for Rare and Neglected Diseases ...
... May 3, 2012 ZyGEM Corp. Ltd., a developer ... DNA and other nucleic acids, today announced it has ... distribution of ZyGEM,s DNA and RNA extraction products in ... a leading provider of quantitative real-time PCR (qPCR) services ...
... SEATTLE, May 3, 2012 CMC Biologics, a leading ... technical excellence in process development and cGMP manufacture ... Manufacturing Company of the Year – Large Category.   The ... partnership with Impact Washington, brought together nearly 300 leaders ...
Cached Biology Technology:MDA Supports Development of 'Dissociative Glucocorticoid' for DMD 2MDA Supports Development of 'Dissociative Glucocorticoid' for DMD 3ZyGEM Teams With TATAA Biocenter To Distribute Its Innovative Nucleic acid Extraction Kits 2ZyGEM Teams With TATAA Biocenter To Distribute Its Innovative Nucleic acid Extraction Kits 3CMC Biologics Honored as Finalist for Washington's Manufacturing Company of the Year Award 2
(Date:9/2/2014)... losing weight is enough to prevent Type 2 diabetes, don,t ... 2014 issue of The FASEB Journal , ... Type 2 diabetes. This study compared genetically identical twins-one heavier ... the circulating metabolites, including those related to Type 2 diabetes, ... These findings suggest that the onset of this type of ...
(Date:9/2/2014)... birds, also known as perching birds, that migrate by ... do in autumn to reach their destinations. This seasonal ... that only make short migratory flights, says researcher Cecilia ... Behavioral Ecology and Sociobiology . , Nilsson, ... a tracking radar to measure over three years the ...
(Date:9/2/2014)... the last decade in Taiyuan, China, have substantially improved ... greater than 50% reduction in costs associated with loss ... to researchers at the Columbia Center for Children,s Environmental ... the Shanxi Medical University, the Center of Diseases Control ... School of Public Health. , The study is the ...
Breaking Biology News(10 mins):What you eat and not just the number of calories, is a significant factor in diabetes risk 2Migrating birds sprint in spring, but take things easy in autumn 2Clean air halves health costs in Chinese city 2
... at least 20 percent of adults in the United ... that prevents bones from rubbing together. By studying the ... how the earliest stages of arthritis make the tissue ... running or jumping. The findings could help researchers ...
... ARBOR, Mich. For nearly two years, University of Michigan ... clinical trial of stem cell injections in patients with the ... ALS or Lou Gehrig,s disease. Now, a new ... way for U-M to become the second site in the ...
... sometimes called "hardening of the arteries" is ... countries. A cell-permeable peptide containing the NF-ĸB nuclear localization ... controlling the development of atherosclerotic disease. This study is ... American Journal of Pathology . Atherosclerosis is a ...
Cached Biology News:Hop, skip or jump? Study says no to all of the above 2Hop, skip or jump? Study says no to all of the above 3FDA approves Phase II of stem cell trial for ALS led by U-M's Dr. Eva Feldman 2Cell-permeable peptide shows promise for controlling cardiovascular disease 2
... The Fujifilm Life Science FLA-8000 Fluorescent Image ... in a single laser imaging system. This ... samples labeled with fluorescent dyes or radioisotopes ... most demanding laboratories. Speed, image quality and ...
...
...
... PC, is used to perform runs ... from the Experion automated electrophoresis system. ... and simulated gel views and summarizes ... a Results table. This software is ...
Biology Products: